Published by Josh White on 19th August 2025
(Sharecast News) - Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for schizophrenia.
URL: http://www.digitallook.com/dl/news/story/35296160/...